AstraZeneca Pharma India Ltd Q2 FY26 – The ₹5,590.9 Mn Prescription Party: 37% Revenue Surge, NPPA Show-Cause Drama, and a Rare-Disease Launch Fiesta!
1. At a Glance
If corporate life were a Bollywood medical thriller, AstraZeneca Pharma India Ltd (AZPIL) would be the suave doctor who aces surgeries, wins awards, and still finds time to fight regulators. With a market cap of ₹22,694 crore and a stock price of ₹9,078, the company looks like that posh South Delhi clinic that never discounts consultation fees.
The latest Q2 FY26 numbers screamed “Big Pharma is back!” — Revenue ₹5,590.9 million (₹559 crore), up a healthy 37% YoY, while PAT jumped 51% to ₹58.1 crore. If that wasn’t enough, it launched Eculizumab (Soliris) for rare blood disorders and secured seven CDSCO approvals, including a new one for Enhertu and additional indications for Imfinzi and Durvalumab.
But drama is never far in pharma. In September, the company got slapped with a show-cause notice from NPPA for allegedly overcharging ₹60.5 crore on its Symbicort inhaler. Because what’s success without a little controversy?
Still, the company flaunts a ROE of 23.6%, ROCE of 33.4%, and almost zero debt (₹34.8 crore) — numbers that would make even the CFO of Cipla briefly jealous.
So, should investors fall in love with this pharma prodigy or wait till the NPPA dust settles? Let’s dissect the patient.
2. Introduction
Welcome to AstraZeneca India, the desi arm of the British pharmaceutical aristocracy. If Big Pharma were a royal family, this one would be sipping Darjeeling tea in Hyderabad while plotting how to treat every possible disease — from diabetes to cancer — with a side of elegance.
Once known mainly for the COVID-19 vaccine fame of its parent, AstraZeneca India has quietly transformed into a powerhouse for oncology and CVRM (Cardio-Vascular, Renal, Metabolic) drugs. Brands like Tagrisso, Brilinta, Forxiga, and Symbicort aren’t just medicines — they’re practically household names in hospital corridors.
In FY25, revenue zoomed to ₹17,163 million, a 32% YoY growth, while FY26 started with a bang: Q2 alone clocked ₹5,590.9 million — the company’s strongest quarter ever recorded.
And yet, this is a company that doesn’t manufacture anymore — it surrendered its manufacturing license in September 2025. Yes, you read that right. AstraZeneca India now fully embraces the marketing, distribution, and import model — or as pharma insiders call it, “asset-light, profit-right.”
Between approvals, launches, and show-cause letters, the company is having one of the busiest years in its 45-year Indian history.
3. Business Model – WTF Do They Even Do?
AstraZeneca Pharma India isn’t out there mixing APIs in beakers or running chemical experiments in basements. Instead, it’s more like a classy drug distributor — importing and marketing high-end patented therapies developed by its global parent.
Here’s the simplified version:
They don’t make the drugs (since September 2025).
They market and sell them under the AstraZeneca global brand.
They focus on high-margin specialty therapies — mostly in Oncology, Cardiovascular, Diabetes, and Respiratory segments.
Their product portfolio includes blockbusters like:
Tagrisso (lung cancer)
Imfinzi (immuno-oncology)
Forxiga (heart failure and kidney disease)
Brilinta (heart health)
Symbicort (respiratory)
With 94% of revenue from India and 6% from exports, AstraZeneca India is fully desi in operations but totally videsi in ownership — 75% held by AstraZeneca Pharmaceuticals AB (Sweden).
They’ve also built an innovation hub — the India Sweden Healthcare Innovation Centre (ISHIC) — that promotes early diagnosis using AI, especially for non-communicable diseases. Basically, it’s their way of saying, “We’ll use tech to spot your cholesterol before you even order that next samosa.”
4. Financials Overview
Quarterly Performance (₹ in Crores)
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue
559
408
526
37.0%
6.3%
EBITDA
75
53
81
41.5%
-7.4%
PAT
54
38
56
42.1%
-3.6%
EPS (₹)
21.7
15.4
22.3
41.0%
-2.9%
AstraZeneca’s EPS annualized = ₹21.7 × 4 = ₹86.8. At a CMP of ₹9,078, the P/E = 104x. “P/E not meaningful”? Nah, just MNC pricing.
Commentary: That 37% revenue jump is what happens when rare-disease drugs enter the chat. The EBITDA margin at 13% may seem modest, but given their minimal capital needs, it’s pure cash flow charm. PAT growth at 42% YoY shows that marketing-led pharma still has punch.
Fair value (if re-rated to peer average): ₹7,000–₹9,000
Method 3: DCF (Simplified) Assuming:
15% growth for 5 years, 8% WACC, 4% terminal growth. → Fair value = ₹8,000 – ₹9,500
Fair Value Range (Educational Only): ₹6,000–₹9,500 per share
Disclaimer: This fair value range is for educational purposes only and not investment advice. But if you ever find AstraZeneca below ₹6,000, even doctors might start buying shares instead of stethoscopes.
6. What’s Cooking – News, Triggers, Drama
August–November 2025 has been busier for AstraZeneca than a cardiologist during Diwali season.
Eculizumab (Soliris) launched in India (Aug 2025) for rare blood disorders – because “niche therapy” is the new luxury brand.
Lokelma launched (Oct 2025) for treating hyperkalemia — yes, they’re selling powder that balances your potassium like a dietitian with a chemistry degree.
Multiple CDSCO approvals: Forxiga, Imfinzi, Enhertu, and Durvalumab all got shiny new indications.
Management change: Dr. Sanjeev Panchal resigned; Mr.
